EGFR and hepatocellular carcinoma: As Zhao et al. observed, anti-PD-L1 therapy reduced resistance to cetuximab (an anti-EGFR treatment) by inhibiting the formation of the PD-L1/EGFR/ITGB4 triad, thereby reducing the accumulation of LDs, TGs, and CHO within HCC cells [55].